Skip to main content
CELL BIOTECH CO ., LTD logo

CELL BIOTECH CO ., LTD — Investor Relations & Filings

Ticker · 049960 ISIN · KR7049960008 KO Manufacturing
Open in API
Filings indexed 189 across all filing types
Latest filing 2020-03-26 Declaration of Voting R…
Country KR South Korea
Listing KO 049960

About CELL BIOTECH CO ., LTD

https://www.cellbiotech.com/

CELL BIOTECH CO., LTD. is a biotechnology company specializing in the research, development, and manufacturing of probiotic solutions. With over three decades of experience, the company leverages its proprietary, worldwide-patented dual-coating technology, which is designed to ensure a higher survival rate for probiotic strains as they pass through the gastrointestinal tract. The company develops and utilizes its own GRAS (Generally Recognized as Safe) certified strains for its products. Its business encompasses the production of finished consumer products, such as the DUOLAC brand, and providing customized OEM/ODM services for the pharmaceutical and food supplement sectors.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the resolutions passed during the meeting, including financial statement approval, dividend declarations, director appointments, and business purpose changes. This aligns perfectly with the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2020-03-26 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a formal regulatory filing titled 'Audit Report Submission' (감사보고서 제출) from Cell Biotech. It provides the auditor's opinion (unqualified/appropriate), key financial data (assets, liabilities, revenue, profit), and confirms the receipt of the audit report. While it contains financial data, it is a summary disclosure of the audit results rather than the full 10-K annual report itself. In the context of Korean regulatory filings (DART/KIND), this is a standard 'Audit Report Submission' filing, which falls under the 'Audit Report / Information' category. FY 2019
2020-03-18 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Cell Biotech. It contains the agenda for the 25th Annual General Meeting, including reports on financial statements, board appointments, and dividend proposals. While it contains financial data, it is primarily a formal notice and proxy-related document sent to shareholders to inform them of the meeting details and agenda items, which falls under the category of Proxy Solicitation & Information Statement.
2020-03-10 Korean
의결권대리행사권유참고서류
AGM Information Classification · 100% confidence The document is a 'Reference Document' (참고서류) for an Annual General Meeting (AGM) of Cell Biotech. It includes details about the solicitor, voting rights, and the agenda for the 25th Annual General Meeting, including financial statements (balance sheets, income statements, etc.) to be approved by shareholders. This aligns perfectly with the definition of AGM Information (AGM-R), which covers materials shared during the AGM.
2020-03-10 Korean
주주총회집중일개최사유신고
Regulatory Filings Classification · 95% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the 'Report of Reason for Holding a General Meeting of Shareholders on a Concentrated Date'. It explains why the company is holding its AGM on a date that coincides with other companies' meetings, citing audit report timelines and consolidated financial statement preparation. As this is a specific regulatory disclosure regarding meeting logistics rather than the meeting materials themselves or a proxy statement, it falls under the general regulatory filing category.
2020-03-10 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 95% confidence The document is a regulatory filing from a Korean company (Cell Biotech) announcing a significant change (over 30%) in revenue or profit structure. This is a standard disclosure requirement in the Korean market (DART system) for preliminary earnings results. Since it provides key financial highlights and reasons for the variance rather than being a full annual report or a simple announcement of a report's availability, it falls under the Earnings Release category. FY 2019
2020-02-25 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.